Patents by Inventor Laura Kay Shawver
Laura Kay Shawver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7202265Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1? position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.Type: GrantFiled: February 24, 2004Date of Patent: April 10, 2007Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Connie Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
-
Patent number: 6906093Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.Type: GrantFiled: July 3, 2001Date of Patent: June 14, 2005Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
-
Patent number: 6846839Abstract: The present invention relates to methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis. More specifically, this invention relates to methods for treating diseases and disorders, such as rheumatoid arthritis, endometriosis, ocular neovascularization, solid tumor growth and metastases, and excessive scarring during wound healing, with indolinone compounds.Type: GrantFiled: June 16, 1999Date of Patent: January 25, 2005Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Li Sun, Laura Kay Shawver, Klaus Peter Hirth, Annie Fong
-
Publication number: 20040102489Abstract: The present invention relates to novel heteroaryl-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.Type: ApplicationFiled: November 17, 2003Publication date: May 27, 2004Applicant: Sugen, Inc.Inventors: Gerald McMahon, Peng Cho Tang, Laura Kay Shawver, Klaus Peter Hirth
-
Patent number: 6696448Abstract: The present invention relates to novel 3-(piperazinyl-benylidenyl)-2-indolinone compounds and derivatives and physiologically acceptable salts thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.Type: GrantFiled: July 24, 2002Date of Patent: February 24, 2004Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Laura Kay Shawver, Klaus Peter Hirth
-
Patent number: 6649635Abstract: The present invention relates to novel heteroaryl-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.Type: GrantFiled: September 7, 2001Date of Patent: November 18, 2003Assignee: Sugen, Inc.Inventors: Gerald McMahon, Peng Cho Tang, Laura Kay Shawver, Klaus Peter Hirth
-
Publication number: 20030108946Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1′ position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.Type: ApplicationFiled: February 19, 2002Publication date: June 12, 2003Applicant: SUGEN, Inc.Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
-
Publication number: 20030069421Abstract: The present invention relates to novel 3-(piperazinyl-benylidenyl)-2-indolinone compounds and derivatives and physiologically acceptable salts thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.Type: ApplicationFiled: July 24, 2002Publication date: April 10, 2003Applicant: SUGEN, Inc.Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Laura Kay Shawver, Klaus Peter Hlrth
-
Publication number: 20020102608Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.Type: ApplicationFiled: July 3, 2001Publication date: August 1, 2002Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
-
Publication number: 20020065283Abstract: The present invention relates to novel heteroaryl-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.Type: ApplicationFiled: September 7, 2001Publication date: May 30, 2002Inventors: Gerald McMahon, Peng Cho Tang, Laura Kay Shawver, Klaus Peter Hirth
-
Publication number: 20020022626Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1′ position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.Type: ApplicationFiled: July 13, 2000Publication date: February 21, 2002Inventors: Peng Cho Tang, LI Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
-
Patent number: 6335356Abstract: The present invention features pharmaceutical formulations containing a lipophilic compound such as leflunomide. The lipophilic compound is solubilized in solution containing alcohol and a surfactant. The solubilized compound can then be further dissolved in a pharmaceutically acceptable aqueous solution, such as WFI (water for injection), D5W (5% dextrose in water) or D5W ½ N saline, to form a pharmaceutical formulation suitable for patient administration. The formulation is preferably used for parenteral administration.Type: GrantFiled: March 1, 2000Date of Patent: January 1, 2002Assignee: Sugen, Inc.Inventors: Donna Pruess Schwartz, Laura Kay Shawver
-
Patent number: 6316479Abstract: The present invention relates to novel isoxazole-4-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.Type: GrantFiled: May 19, 1998Date of Patent: November 13, 2001Assignee: Sugen, Inc.Inventors: Gerald McMahon, Peng Cho Tang, Laura Kay Shawver, Klaus Peter Hirth
-
Patent number: 6147106Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1' position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.Type: GrantFiled: August 20, 1997Date of Patent: November 14, 2000Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
-
Patent number: 5990141Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.Type: GrantFiled: January 6, 1995Date of Patent: November 23, 1999Assignee: Sugen Inc.Inventors: Klaus Peter Hirth, Donna Pruess Schwartz, Elaina Mann, Laura Kay Shawver, Gyorgi Keri, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Axel Ullrich, Reiner Lammers, Fairooz F. Kabbinavar, Dennis Slamon, Peng Cho Tang
-
Patent number: 5958959Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDFG-R superfamily and are selective for members of the PDGF-R superfamily. The PDGF-R superfamily includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.Type: GrantFiled: June 1, 1995Date of Patent: September 28, 1999Assignees: Sugen, Inc., Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.Inventors: Klaus Peter Hirth, Donna Pruess Schwartz, Elaina Mann, Laura Kay Shawver, Axel Ullrich, Reiner Lammers
-
Patent number: 5932602Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.Type: GrantFiled: June 1, 1995Date of Patent: August 3, 1999Assignees: Sugen, Inc., Biosignal Ltd., The Regents of the University of California, Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V., Yissum Research and Development Company of the Hebrew University of JerusalemInventors: Klaus Peter Hirth, Laura Kay Shawver, Gyorgi Keri, Istvan Szekely, Janis Haimichael, Axel Ullrich, Reiner Lammers
-
Patent number: 5783592Abstract: The present invention features pharmaceutical formulations containing a lipophilic compound that is solubilized in a solution containing ethanol and a surfactant. The solubilized compound can then be further dissolved in a pharmaceutically acceptable aqueous solution, such as WFI (water for injection), D5W (5% dextrose in water) and D5W 1/2 N saline, to form a pharmaceutical formulation suitable for patient administration. The formulation is preferably used for parenteral administration.Type: GrantFiled: March 6, 1997Date of Patent: July 21, 1998Assignee: Baylor College of MedicineInventors: Donna Pruess Schwartz, Laura Kay Shawver
-
Patent number: 5700822Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.Type: GrantFiled: June 1, 1995Date of Patent: December 23, 1997Assignee: The Regents of the University of CaliforniaInventors: Klaus Peter Hirth, Donna Pruess Schwartz, Elaina Mann, Laura Kay Shawver, Gyorgi Keri, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Axel Ullrich, Reiner Lammers, Fairooz F. Kabbinavar, Dennis Slamon, Peng Cho Tang
-
Patent number: 5700823Abstract: Method for treating a patient inflicted with a cell proliferation disorder, such as a cancer, characterized by inappropriate PDGF-R activity. The method involves the step of administering to the patient a therapeutically effective amount of a composition described in application.Type: GrantFiled: January 7, 1994Date of Patent: December 23, 1997Assignees: Sugen, Inc., Biosignal L.T.D., Yissum Research Development Company, Hebrew University of Jerusalem, Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Klaus Peter Hirth, Donna Pruess Schwartz, Elaina Mann, Laura Kay Shawver, Gyorgy Keri, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Axel Ullrich, Reiner Lammers